"Phase converters add another layer of complexity to any facility," writes Michael Baldauf in this Tech Tips article.

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the Ideal Power ...

MUNICH, May 14, 2025 /PRNewswire/ -- CHINT Global wrapped up three vibrant days at Intersolar Europe 2025 , one of the ...

Samsung E&A and Svante Technologies collaborate to deploy modular carbon capture plants, leveraging advanced technologies to ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

The FDA has approved the SAPIEN 3 platform, a TAVR therapy, for patients with severe aortic stenosis without symptoms.

Amgen still needs to show that the reduction in Lp(a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol a ...

Explore Ideal Power's Q1 2025 earnings insights! Learn about accelerating revenue ramps, Stellantis partnerships, and solid-state breaker milestones.